Go to
current issue
加入关注
本刊介绍/投稿指南
催更
样式： 排序： IF: - GO 导出 标记为已读
-
Washout periods in inflammatory bowel disease trials: A systematic literature review and proposed solutions Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Pauline Wils, Vipul Jairath, Bruce E. Sands, Walter Reinisch, Silvio Danese, Laurent Peyrin-Biroulet
Abstract not available
-
The diagnostic performance of fecal immunochemical tests for detecting advanced neoplasia at surveillance colonoscopy. Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Grace Berwald, Graeme P. Young, Charles Cock, Peter Bampton, Robert Fraser, Erin L. Symonds
Background and Aims An increasing burden on healthcare resources has resulted in a backlog of individuals requiring colonoscopy, with delays in surveillance possibly detrimental for individuals at increased risk of colorectal cancer (CRC). This study investigated the use of a two-sample fecal immunochemical test (FIT to establish those most likely to have advanced neoplasia (AN) and in need of prioritized
-
The Index of Severity for Eosinophilic Esophagitis (I-SEE) Reflects Longitudinal Clinicopathologic Changes in Children Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Andrew Dickerson, Ayse Kolemen, Keeler Kime, Kira Chaiboonma, Ranjan Dohil, Glenn T. Furuta, Evan S. Dellon, Seema S. Aceves
Background and Aims The Index of Severity for EoE (I-SEE) was recently developed. We aimed to understand I-SEE scores in a longitudinal pediatric cohort and to determine the relationship between I-SEE and clinical features in children. Methods We performed a retrospective analysis on a prospectively enrolled cohort of children at a single center who were treated as part of routine clinical care. I-SEE
-
A Computer-Aided Detection (CADe) System Significantly Improves Polyp Detection in Routine Practice Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Rajesh N. Keswani, Urvi Thakkar, Alexandra Sals, John E. Pandolfino
Abstract not available
-
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER) Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Jean-Frederic Colombel, Ryan C. Ungaro, Bruce E. Sands, Corey A. Siegel, Douglas C. Wolf, John F. Valentine, Brian G. Feagan, Blue Neustifter, Harisha Kadali, Pradeep Nazarey, Alexandra James, Vipul Jairath, Rana M. Qasim Khan
BACKGROUND & AIMS Although biologics have revolutionized treatment of Crohn’s disease (CD), an efficacy ceiling has been reached. Combining biologic therapies may improve remission rates. METHODS EXPLORER, a phase 4, single-arm, open-label study, evaluated triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, then every 8 weeks), adalimumab (160 mg on day 2, 80 mg at week 2,
-
An analysis of delayed bleeding in cases of colorectal endoscopic submucosal dissection due to types of direct oral anticoagulants in Japan Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Naohisa Yoshida, Yoshikazu Hayashi, Daichi Togo, Shiro Oka, Kazunori Takada, Shusei Fukunaga, Yoshinori Morita, Takemasa Hayashi, Kazuhiro Kozuka, Yosuke Tsuji, Takashi Murakami, Takeshi Yamamura, Yoriaki Komeda, Yoji Takeuchi, Kensuke Shinmura, Hiroko Fukuda, Shinji Yoshii, Shoko Ono, Shinichi Katsuki, Kazumasa Kawashima, Naoyuki Yamaguchi
-
In response to: Australasian insights and perspectives on the burden of Chronic Liver Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 James M. Paik, Linda Henry, Zobair M. Younossi
Abstract not available
-
A Rare Case of Esophageal Granular Cell Tumor in Eosinophilic Esophagitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Yousaf Abughofah, Grace E. Kim, Dennis Chen
Abstract not available
-
This Letter to the Editor is in response to: “Efficacy of Elimination Diets in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis”. Christoph Mayerhofer. Volume 21, Issue 9, P2197-2210, August 2023 Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 M.J. Warners, A.J. Bredenoord
Abstract not available
-
Reply to the Letter to the Editor: “Glucagon-like Peptide-1 Receptor Agonists: Best Choice for Patients with Cirrhosis and Diabetes?” Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Fu-Shun Yen, Teng-Shun Yu, Chih-Cheng Hsu, Chii-Min Hwu
Abstract not available
-
Development and Current State of Digital Therapeutics for Irritable Bowel Syndrome Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-22 Darren M. Brenner, Amy M. Ladewski, Sarah Wimberly Kinsinger
Background Irritable bowel syndrome (IBS) is a common, debilitating disorder characterized by abdominal pain and disordered bowel habits. Current pharmacological treatments often provide incomplete symptom relief and may be poorly tolerated. Furthermore, alleviation of gastrointestinal symptoms does not always translate into improved quality of life (QOL) for IBS patients. Current treatment guidelines
-
-
Editorial Board Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
Table of Contents Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
Elsewhere in the AGA Journals Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
Blue Notes Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21 Charles J. Kahi
Abstract not available
-
Parental Leave and Return-to-Work Policies: A Practical Model for Implementation in Gastroenterology Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21 Lauren D. Feld, Amy S. Oxentenko, Dawn Sears, Aline Charabaty, Loren G. Rabinowitz, Julie K. Silver
Abstract not available
-
Exam 1: Tools to Measure the Impact of Structural Racism and Discrimination on Gastrointestinal and Hepatology Disease Outcomes: A Scoping Review Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
Exam 2: Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-21
Abstract not available
-
-
Global Prevalence of Fecal Incontinence in Community-Dwelling Adults: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-19 Isabelle Mack, Heiko Hahn, Celina Gödel, Paul Enck, Adil E. Bharucha
-
Sex differences in treatment response to nucleos(t)ide therapy in chronic hepatitis B: a multicenter longitudinal study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-19 Angela Chau, Ming-Lun Yeh, Pei-Chien Tsai, Daniel Q. Huang, Sung Eun Kim, Huy Trinh, Eileen L. Yoon, Hyunwoo Oh, Jae Yoon Jeong, Sang Bong Ahn, Jihyun An, Cheng-Hao Tseng, Yao-Chun Hsu, Soung Won Jeong, Yong Kyun Cho, Jae-Jun Shim, Hyoung Su Kim, Takanori Ito, Sebastián Marciano, Keigo Kawashima, Mindie H. Nguyen
Background It is unclear if there may be sex differences in response to nucleos(t)ide analogs (NA) including viral suppression [VR], biochemical response [BR], complete response [CR], and HCC incidence among hepatitis B patients. We compared NA treatment outcomes by sex. Approach A retrospective cohort study of 3388 treatment-naïve adult hepatitis B patients (1250 female; 2138 male) from the REAL-B
-
Long-term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data over Eight Years from the Hong Kong FMT Registry Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-19 Yuk Kam Yau, Louis Ho Shing Lau, Rashid Nok Shun Lui, Sunny Hei Wong, Cosmos Liutao Guo, Joyce Wing Yan Mak, Jessica Yuet Ling Ching, Margaret Ip, Michael A. Kamm, David T. Rubin, Paul Kay Sheung Chan, Francis Ka Leung Chan, Siew Chien Ng
-
HLADQA1*05G>A genetic-screening promotes the safe delivery of combination therapy in inflammatory bowel disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-19 Aze Wilson, Nilesh Chande, Terry Ponich, James C. Gregor, Yun-hee Choi, Richard B. Kim
Abstract not available
-
The Grim Side of Microscopic Colitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-18 Ayokunle T. Abegunde
Abstract not available
-
Hemosuccus pancreaticus caused by splenic artery pseudoaneurysm: Two cases diagnosed and treated with EUS Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-18 Mehdi Mohamadnejad, Ali Ali Asgari, Mohammad Al-Haddad
Abstract not available
-
Malignant IPMN with underlying annular pancreas Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-18 Seung-Ho Sin, Hyung-Keun Kim, Huin-Suk Chae
Abstract not available
-
PREVALENCE AND PREDICTORS OF BARRETT’S ESOPHAGUS AFTER NEGATIVE INITIAL ENDOSCOPY: ANALYSIS FROM TWO NATIONAL DATABASES Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Lovekirat Dhaliwal, Amrit K. Kamboj, J. Lucas Williams, Apoorva K. Chandar, Karan Sachdeva, Erin Gibbons, Ramona Lansing, Melissa Passe, Jamie A. Perez, Katelin L.R. Avenir, Scott A. Martin, Cadman L. Leggett, Amitabh Chak, Gary W. Falk, Sachin Wani, Nicholas J. Shaheen, John B. Kisiel, Prasad G. Iyer
Introduction Guidelines suggest a single screening esophagogastroduodenoscopy (EGD) in patients with multiple risk factors for Barrett’s esophagus (BE). We aimed to determine BE prevalence and predictors on repeat EGD after a negative initial EGD, using two large national databases (GI Quality Improvement Consortium [GIQuIC] and TriNetX). Methods Patients who underwent at least 2 EGDs were included
-
Alpha-1 antitrypsin (AAT) augmentation and the liver phenotype of adults with AAT deficiency (genotype Pi*ZZ) Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Malin Fromme, Karim Hamesch, Carolin V. Schneider, Mattias Mandorfer, Monica Pons, Katrine Thorhauge, Vitor Pereira, Jan Sperl, Sona Frankova, Matthias C. Reichert, Federica Benini, Barbara Burbaum, Moritz Kleinjans, Samira Amzou, Laura Rademacher, Lisa Bewersdorf, Jef Verbeek, Frederik Nevens, Joan Genesca, Marc Miravitlles, Pavel Strnad
Background and aims Alpha-1 antitrypsin (AAT) is a major protease inhibitor produced by hepatocytes. The most relevant AAT mutation giving rise to AAT deficiency (AATD), the ‘Pi*Z’ variant, causes harmful AAT protein accumulation in the liver, shortage of AAT in the systemic circulation and thereby predisposes to liver and lung injury. Although intravenous AAT augmentation constitutes an established
-
Accuracy, reliability and comprehensiveness of ChatGPT generated medical responses for patients with NAFLD Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Nicola Pugliese, Vincent Wai-Sun Wong, Jörn M. Schattenberg, Manuel Romero-Gomez, Giada Sebastiani, , Alessio Aghemo
Abstract not available
-
Withdrawal of Immunomodulators or TNF Antagonists in Patients with Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 David J. Katibian, Virginia Solitano, D. Brent Polk, Tran Nguyen, Christopher Ma, Gaurav Syal, Taku Kobayashi, Toshifumi Hibi, Sine Buhl, Mark Andrew Ainsworth, Vipul Jairath, Siddharth Singh
-
Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Peter Ueda, Viktor Wintzell, Mads Melbye, Björn Eliasson, Jonas Söderling, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Henrik Svanström, Anders Hviid, Björn Pasternak
-
Biologics in the Treatment of Eosinophilic Esophagitis: Ready for Use? Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-15 Diana L. Snyder, Evan S. Dellon
Abstract not available
-
Endoscopic resection of cecal neoplasia with full-thickness resection of the appendiceal stump using double-layered suturing Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-14 Daiki Kitagawa, Shunsuke Yoshii, Ryu Ishihara
Abstract not available
-
Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma with Varices using Red Dichromatic Imaging Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-14 Tomoya Ueda, Takashi Kanesaka, Ryu Ishihara
Abstract not available
-
-
Spectrum and excess risk of gastrointestinal tumors in Li-Fraumeni syndrome Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-14 Jessica N. Hatton, Kelvin C. de Andrade, Megan N. Frone, Sharon A. Savage, Payal P. Khincha
Abstract not available
-
What are clinically significant endoscopic findings? Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-13 Bahattin Cicek, Erkin Oztas
Abstract not available
-
Crohn’s Disease: an Equal Opportunity Burden Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-13 Florence-Damilola Odufalu, Edward V. Loftus, Sophie Balzora
Abstract not available
-
Letter on “Achalasia is Strongly Associated with Eosinophilic Esophagitis and Other Allergic Disorders” Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-13 Yun-Feng Li, Shuo-Yan Gau
Abstract not available
-
Is Increased Caloric Intake a Feature of NAFLD Regardless of the Presence of Obesity Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-13 Andrew Szilagyi
Abstract not available
-
Cannabinoids and the GI Tract Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-09 Michael Camilleri, D.Sc. Ting Zheng
The synthesis and degradation of endocannabinoids, location of cannabinoid (CB) receptors, and cannabinoid mechanisms of action on immune/inflammatory, neuromuscular, and sensory functions in digestive organs are well documented. CB2 mechanisms are particularly relevant in immune and sensory functions. Increasing use of cannabinoids in the USA is impacted by social determinants of health including
-
Anti-Mullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-09 Stephanie S. Maldonado, Marcelle I. Cedars, Katherine P. Yates, Laura A. Wilson, Ryan Gill, Norah A. Terrault, Ayako Suzuki, Monika A. Sarkar
Background & Aims Anti-müllerian hormone (AMH) is a marker of ovarian reserve with emerging data linking lower levels to some metabolic and inflammatory diseases in women. Whether AMH levels influence nonalcoholic fatty liver disease (NAFLD) is unknown. Methods: Leveraging the NASH Clinical Research Network we determined the association of AMH levels within 6 months of liver biopsy with presence and
-
Loneliness and Depressive Symptoms are High Among Older Adults with Digestive Disease and associated with Lower Perceived Health Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-09 Shirley Cohen-Mekelburg, Ariel Jordan, Brooke Kenney, Helen J. Burgess, Joy W. Chang, Hsou Mei Hu, Elliot Tapper, Kenneth M. Langa, Deborah A. Levine, Akbar K. Waljee
Background and Aims Current approaches to managing digestive disease in older adults fail to consider the psychosocial factors contributing to a person’s health. We aimed to compare the frequency of loneliness, depression, and social isolation in older adults with and without a digestive disease and to quantify their association with poor health. Methods We conducted an analysis of Health and Retirement
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) in inflammatory bowel disease (IBD): a proposed stepwise approach Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-09 Virginia Solitano, Antonio Moschetta
Abstract not available
-
Pinstripe pattern of esophageal achalasia demonstrated with texture and color enhancement imaging Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-07 Yugo Iwaya, Takuma Okamura, Tadanobu Nagaya
Abstract not available
-
Optimizing the management algorithm for heartburn in general gastroenterology: Cost-effectiveness and cost-minimization analysis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-07 Eric D. Shah, Walter W. Chan, Daniela Jodorkovsky, Kristle Lee Lynch, Amit Patel, Dhyanesh Patel, Rena Yadlapati
-
Incidence of Etiology-specific Hepatocellular Carcinoma: diverging trends and significant heterogeneity by race and ethnicity Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-06 Paulo S. Pinheiro, Patricia D. Jones, Heidy Medina, Hannah M. Cranford, Tulay Koru-Sengul, Tim Bungum, Robert Wong, Erin N. Kobetz, Katherine A. McGlynn
-
GLP-1 Receptor Agonist Treatment in Liver Cirrhosis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-06 Cheng Han Ng, Pojsakorn Danpanichkul, Mark Muthiah
Abstract not available
-
Being Breastfed in Infancy and Risk of Colorectal Cancer and Precursor Lesions Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-06 Chen Yuan, Qiao-Li Wang, Hanseul Kim, Ana Babic, Jinming Zhang, Brian M. Wolpin, Kana Wu, Mingyang Song, Shuji Ogino, Jeffrey A. Meyerhardt, Andrew T. Chan, Yin Cao, Edward L. Giovannucci, Kimmie Ng
BACKGROUND & AIMS Emerging evidence implicates the importance of perinatal and early-life exposures in colorectal cancer (CRC) development. However, it remains unclear whether being breastfed in infancy is associated with CRC risk in adult life, particularly early adulthood. METHODS We prospectively investigated the association between history of being breastfed and risk of CRC and its precursor lesions
-
Early Detection of Pancreatic Cancer: Considerable Advances, but Still a Long Way to Go Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-06 Ruiyuan Xu, Chengcheng Wang, Yupei Zhao
Abstract not available
-
Comparative Effectiveness of Upadacitinib Versus Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-05 Rahul S. Dalal, Govind Kallumkal, Heidy J. Cabral, Salam Bachour, Edward L. Barnes, Jessica R. Allegretti
Abstract not available
-
Comparative effectiveness of biologic therapies in preventing penetrating complications in patients with Crohn’s disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-04 Jeffrey D. McCurdy, Dustin Stwalley, Margaret A. Olsen, Parakkal Deepak
Background and Aims Comparative effectiveness of biologics in preventing penetrating disease (PD) in Crohn’s disease (CD) is not well established. We compared the risk of developing luminal and perianal PD (LPD and PPD) between biologics used as first-line therapies. Methods Adults (>17 years) with CD who initiated their first biologic (anti-tumor necrosis factor [anti-TNF], ustekinumab ([UST]) or
-
Real-world efficacy of dupilumab in severe, treatment-refractory, and fibrostenotic patients with eosinophilic esophagitis Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-03 Christopher J. Lee, Evan S. Dellon
Background and Aims Dupilumab is approved for treatment of eosinophilic esophagitis (EoE), but real-world data are lacking. We aimed to determine the real-world efficacy of dupilumab in patients with severe, treatment refractory, and fibrostenotic EoE. Methods We conducted a retrospective cohort study of EoE patients prescribed dupilumab and who were treatment-refractory to standard modalities. Patient
-
Glucagon-like Peptide-1 Receptor Agonists: Best Choice for Patients with Cirrhosis and Diabetes? Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-03 Yuanyuan Li, Xiaoze Wang
Abstract not available
-
”Secondary prevention of esophageal variceal bleeding: Still a long way to go, but the direction is obvious” Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-03 Hannes Hagström, Ying Shang, Elliot B. Tapper, Axel Wester, Linnea Widman
Abstract not available
-
Natural Evolution of Pancreatic Serous Cystadenoma on EUS (with Video) Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-01 Mehdi Mohamadnejad, Arash Nikmanesh, Mohamad Eloubeidi
Abstract not available
-
Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-Based Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-09-01 Lu Xu, Bingjie He, Yexiang Sun, Jun Li, Peng Shen, Liming Hu, Guozhen Liu, Jinxi Wang, Liping Duan, Siyan Zhan, Shengfeng Wang
Background and aims Limited studies have evaluated the burden of inflammatory bowel disease (IBD) in China. We aimed to estimate the incidence of IBD including ulcerative colitis (UC) and Crohn’s disease (CD) in urban China. Methods The national urban incidence in 2016 was calculated based on urban basic medical insurance from 2012 to 2016 in China by using a 4-year washout period. The incidence in
-
Age-dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-08-31 Chuan Pang, Jian-Ming Li, Zhen Wang, Yan-Chun Luo, Zhi-Gang Cheng, Zhi-Yu Han, Fang-Yi Liu, Xiao-Ling Yu, Feng Liang, Hong-Qing Xi, Rong-Qin Zheng, Wen Cheng, Qiang Wei, Song-Yuan Yu, Qin-Ying Li, Guang-Zhi He, Jie Yu, Ping Liang
Background & Aims Hepatocellular carcinoma (HCC) has higher incidence in males, but the association of sex with survival remains controversial. This study aimed to examine the effect of sex on HCC survival and its association with age. Methods Among 33,238 patients with HCC from 12 Chinese tertiary hospitals, 4,175 patients who underwent curative-intent hepatectomy or ablation were analyzed. Cancer-specific
-
Australasian insights and perspectives on the burden of Chronic Liver Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2023-08-30 Annie Zhou, Rohit Sawhney
Abstract not available
更新日期：2023-09-23
京公网安备 11010802027423号